Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Recombinant DNA01:09

Recombinant DNA

104.7K
Overview
104.7K
Recombinant DNA01:09

Recombinant DNA

23.2K
23.2K
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

26
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
26
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K
Upstream Processing01:27

Upstream Processing

36
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
36
The Central Dogma01:20

The Central Dogma

35.2K
The central dogma explains the flow of genetic information from DNA nucleotides to the amino acid sequence of proteins.
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
35.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant Protein Drugs: A 2025 Update.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same author

Biomimetic Protein Materials for Adjuvant-Free Dermal Penetration.

ACS materials letters·2026
Same author

A Structurally Dynamic Pathogen-Mimicking Biomaterial Is an Efficient Activator of Dendritic Cells.

ACS materials letters·2026
Same author

GFP-like protein scaffolds for antigen grafting: Soluble and stable neoantigen display in mammalian-compatible platforms.

Biomaterials advances·2026
Same author

KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates.

Materials today. Bio·2026

Related Experiment Video

Updated: Mar 26, 2026

Efficient Agroinfiltration of Plants for High-level Transient Expression of Recombinant Proteins
07:50

Efficient Agroinfiltration of Plants for High-level Transient Expression of Recombinant Proteins

Published on: July 23, 2013

51.4K

Recombinant pharmaceuticals from microbial cells: a 2015 update.

Laura Sanchez-Garcia1,2,3, Lucas Martín4, Ramon Mangues5

  • 1Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 08193, Bellaterra, Cerdanyola del Vallès, Spain. laura.sanchezgar@e-campus.uab.cat.

Microbial Cell Factories
|February 11, 2016
PubMed
Summary

Recombinant DNA technology is crucial for producing therapeutic proteins when gene therapy is not feasible. This method enables large-scale production of essential proteins for treating diseases like diabetes and cancer.

More Related Videos

A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells
07:09

A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells

Published on: July 31, 2012

22.1K
A Comparative Analysis of Recombinant Protein Expression in Different Biofactories: Bacteria, Insect Cells and Plant Systems
09:11

A Comparative Analysis of Recombinant Protein Expression in Different Biofactories: Bacteria, Insect Cells and Plant Systems

Published on: March 23, 2015

24.7K

Related Experiment Videos

Last Updated: Mar 26, 2026

Efficient Agroinfiltration of Plants for High-level Transient Expression of Recombinant Proteins
07:50

Efficient Agroinfiltration of Plants for High-level Transient Expression of Recombinant Proteins

Published on: July 23, 2013

51.4K
A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells
07:09

A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells

Published on: July 31, 2012

22.1K
A Comparative Analysis of Recombinant Protein Expression in Different Biofactories: Bacteria, Insect Cells and Plant Systems
09:11

A Comparative Analysis of Recombinant Protein Expression in Different Biofactories: Bacteria, Insect Cells and Plant Systems

Published on: March 23, 2015

24.7K

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Pharmacology

Background:

  • Protein absence or malfunction causes diseases such as diabetes, growth disorders, and clotting disorders.
  • Gene therapy is not yet a viable regular treatment for these protein-related pathologies.
  • Ex vivo production of functional proteins is necessary for therapeutic intervention.

Purpose of the Study:

  • To highlight the importance of recombinant DNA technology in therapeutic protein production.
  • To discuss the evolution of host systems used for producing recombinant proteins.
  • To examine the trend towards engineered proteins with enhanced functionalities.

Main Methods:

  • Review of established and emerging recombinant DNA technologies for protein production.
  • Analysis of various host cell systems including bacteria, yeasts, insect cells, and mammalian cells.
  • Examination of approved and developing recombinant protein-based drugs, particularly for cancer treatment.

Main Results:

  • Recombinant DNA technology is a preferred method for large-scale therapeutic protein production, overcoming limitations of natural extraction and chemical synthesis.
  • Mammalian cells are increasingly utilized as host factories due to their similar protein processing pathways to human cells.
  • Approximately 400 out of 650 approved protein drugs are produced via recombinant technologies, with over 1300 more in development.

Conclusions:

  • Recombinant protein production is vital for treating diseases caused by protein deficiencies or malfunctions.
  • The field is moving towards developing engineered proteins with superior performance and novel functions.
  • Protein-based therapeutics, especially engineered versions, represent a significant and growing area of pharmaceutical development.